The combination of p300/CBP inhibitors and the FLT3 inhibitor quizartinib leads to the mutual suppression of H3K27Ac and FLT3 signaling, resulting in synergistic antitumor effects in in vitro and in vivo models of FLT3-ITD AML. Here, CREBBP is linked to acute myeloid leukemia.